As gene therapies advance toward indications with larger patient populations, adeno-associated virus (AAV) manufacturers are under growing pressure to deliver high-quality vectors at substantially ...

Delivers 2x increase in AAV titers compared to market alternates. Reduce plasmid input, halve the bioreactors, and significantly lower cost per dose. HORSHAM, Pa., Aug. 12, 2025 /PRNewswire/ -- In a ...

In recent years, AAV manufacturing processes have evolved significantly to not only address the need for later-stage clinical and commercial supplies, but also to address regulatory concerns around ...

Scaling a viral vector process from benchtop to clinical supply isn't a bigger version of monoclonal antibody (mAb) manufacturing, but an entirely different analytical challenge. Cell and gene therapy ...